Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.

L, Blonde; EJ, Klein; J, Han; B, Zhang; SM, Mac; TH, Poon; KL, Taylor; ME, Trautmann; DD, Kim; DM, Kendall

doi:10.1111/j.1463-1326.2006.00602.x

Public

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.

Shared by NobleBlocks on Jul 1, 2006 • 12:00 AM UTC

Authors:

Blonde L

Klein EJ

Han J

Abstract

<h4>Aim</h4>Exenatide, an incretin mimetic for the adjunct treatment of type 2 diabetes (DM2), reduced A1C and weight in 30-week placebo-controlled trials. This analysis examined the effects of exenatide on glycaemic control and weight over an 82-week period in patients with DM2 unable to achieve ad...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!